Scientists from IOCB Prague have created compounds a million times more stable than those used to treat tumors or as contrast agents for magnetic resonance imaging.

An important step in countering antibiotic resistance has been made by researchers from IOCB Prague, the Institute of Microbiology and the Institute of Biotechnology of the CAS.

IOCB Prague opened its new branch in Boston, USA on October 18, 2024. The move puts the institute in proximity to scientific institutions, such as Harvard University, MIT, and Boston Medical Center.

Researchers from IOCB Prague are furthering the understanding of how medicines work and what it takes to develop their most effective variants.

Even heavily modified double helices of DNA are stable enough to be used for special applications.

Scientists from the IOCB Prague, in collaboration with the Faculty of Tropical Agriculture of the Czech University of Agriculture in Prague, are solving the mystery of termite life.

Scientists from Dr. Lenka Maletinska's team have developed a new substance that may help to solve the health limitations of obesity and Alzheimer's disease.

Researchers from IOCB Prague, in collaboration with the University of Tübingen, and the Faculty of Science, Charles University, has developed a new type of contrast agent that can be used in both MRI and PET.

A research group led by Dr. Edward Curtis has developed two new types of catalytic DNA molecules (deoxyribozymes) that can reveal the presence of target molecules through fluorescence or color.

Technology from the laboratories of IOCB Prague has been given an extraordinary opportunity to succeed in the rapidly developing segment of gene therapy.